Cardiolipin Remodeling in Mitochondrial Studies: Interpreting MLCL/CL Ratios and Molecular-Species Shifts

Cardiolipin remodeling cannot be inferred from one lipid value. Total cardiolipin (CL), monolysocardiolipin (MLCL), the MLCL/CL ratio, individual CL molecular species, and precursor phospholipids describe different parts of mitochondrial membrane biology. A result may show unchanged total CL but substantial redistribution of acyl chains, or an elevated MLCL/CL ratio driven mainly by loss of CL rather than accumulation of MLCL.

The analytical question is therefore not simply whether cardiolipin changed. It is whether the data distinguish altered synthesis, incomplete remodeling, selective molecular-species loss, mitochondrial depletion, or oxidation. A targeted cardiolipin analysis service can provide the required CL, MLCL, and OxCL measurements, but the biological claim depends on how those measurements are combined and normalized.

Analytical Readouts for Cardiolipin Remodeling

Nascent CL is synthesized from phosphatidylglycerol (PG) and CDP-diacylglycerol in the inner mitochondrial membrane. Its initial acyl-chain distribution is subsequently reshaped by deacylation and reacylation reactions. MLCL is an intermediate in this cycle: one acyl chain has been removed, and reacylation can return it to a mature CL pool. Tafazzin-mediated transacylation, together with other remodeling enzymes and the available phospholipid environment, influences the final tissue-specific molecular-species pattern.

This pathway creates several analytically distinct readouts:

No single readout establishes remodeling on its own. A practical minimum is total CL, total MLCL, the explicitly defined MLCL/CL ratio, and species-resolved CL composition. PG, selected PE/PC species, and OxCL are added when the mechanism requires precursor, acyl-donor, membrane, or oxidative context.

Figure 1. Cardiolipin remodeling studies require parallel measurements of pool size, remodeling intermediates, and molecular-species composition. No single readout substitutes for the others.

MLCL/CL Ratio Interpretation

An elevated MLCL/CL ratio is often treated as a direct marker of defective remodeling. That interpretation is strongest when the numerator and denominator are measured under the same preparation and analytical conditions, both components are reported, and the biological model plausibly affects deacylation or reacylation. The ratio alone is insufficient because mathematically identical increases can arise through different biochemical patterns.

The ratio definition must be explicit. Some studies use total measured MLCL divided by total measured CL; others use selected diagnostic species relative to tetralinoleoyl-CL. These values are not interchangeable. The result table should identify every species included in the numerator and denominator, the integration rule, the response model, and whether components fall below the quantitative range.

Ratios also compress information. A twofold ratio increase does not show whether the effect is driven by a large change in one component or modest changes in both. Report the MLCL and CL components beside the ratio on the same normalization basis. When different standards or response assumptions are used for MLCL and CL, the ratio should be described as method-defined rather than assumed to be an exact molar ratio.

Cardiolipin Molecular-Species Profiling

Total CL can remain stable while its molecular composition changes substantially. A four-acyl-chain lipid can redistribute carbon number and unsaturation without changing the total class pool. In heart and skeletal muscle, tetralinoleoyl cardiolipin—commonly represented as CL 72:8—is often abundant, but it should not be treated as a universal reference species for every tissue, cell line, organism, diet, or culture condition.

Interpretation should begin with the expected baseline composition of the biological system. Brain, liver, heart, skeletal muscle, cultured cells, and non-mammalian samples can have different dominant CL species. Cell-culture medium, serum lot, fatty-acid supplementation, developmental stage, and diet can alter substrate availability. A shift toward longer or more unsaturated CL species may therefore reflect altered acyl supply as well as a change in remodeling enzymes.

Useful summary metrics include:

• abundance of prespecified biologically relevant CL species;
• total measured CL and the fraction contributed by dominant species;
• carbon-number and double-bond distributions;
• a weighted mean carbon number or unsaturation index, with the calculation disclosed;
• the corresponding MLCL molecular-species distribution;
• relationships between CL species and candidate acyl-donor PC or PE pools.

These summaries should not replace the species table. Two groups can have the same mean unsaturation but different underlying species, and sum compositions do not necessarily identify all four acyl chains. Statistical testing should preserve molecular-species results and control the number of comparisons rather than relying only on a class total or heatmap.

Figure 2. Cardiolipin remodeling can redistribute molecular species without changing total CL. Species-level changes and summary composition metrics should be interpreted together.

Mitochondrial Abundance and Cardiolipin Normalization

Whole-tissue and whole-cell measurements combine two variables: how many mitochondria are present and how much CL each mitochondrial membrane contains. A decrease per milligram of tissue can reflect fewer mitochondria, replacement of parenchymal cells by stroma or edema, lower CL per mitochondrion, or selective loss of particular species. Normalizing only to tissue mass or total protein cannot distinguish these possibilities.

Mitochondrial context can be strengthened by measuring an independent indicator of mitochondrial abundance, such as mitochondrial protein markers, citrate synthase activity, mitochondrial DNA copy number, imaging-based mitochondrial content, or the yield of an isolated mitochondrial fraction. None is universal: a treatment can change enzyme activity without changing mitochondrial mass or alter mitochondrial DNA independently of membrane abundance.

Isolated mitochondria reduce cytosolic and non-mitochondrial lipid background but introduce recovery and purity questions. Report starting material, mitochondrial yield, loading basis, and enrichment or contamination markers. Endoplasmic-reticulum, nuclear, lysosomal, and plasma-membrane carryover can influence broader phospholipid context even when CL itself remains mitochondria-enriched.

For whole tissues, provide both sample-level abundance and a mitochondrial-context analysis when possible. If CL per tissue decreases while CL relative to a mitochondrial marker remains stable, altered mitochondrial abundance may be the more parsimonious explanation. If the mitochondrial-context value changes while mitochondrial abundance is stable, remodeling or membrane composition becomes more plausible.

Figure 3. Whole-tissue abundance, cellular normalization, and isolated-mitochondrial measurements answer different questions. Mitochondrial yield and purity must remain visible when interpreting remodeling.

PG, PE, and Acyl Donor Context in Cardiolipin Remodeling

Cardiolipin remodeling occurs within a connected phospholipid system. PG is the immediate biosynthetic precursor of CL, while PC and PE can influence the acyl environment available to transacylation and broader mitochondrial membrane composition. A focused phosphatidylglycerol analysis can help determine whether a CL phenotype is accompanied by a precursor-pool shift.

• Low CL with accumulated PG: compatible with impaired conversion or altered downstream CL maintenance, but requires enzyme and flux context.
• Low CL and low PG: may reflect broader phospholipid or mitochondrial loss rather than a selective remodeling block.
• Stable total CL with loss of a dominant mature species: consistent with species redistribution; inspect MLCL and alternative CL species before calling net depletion.
• Elevated MLCL with altered PC/PE acyl composition: may connect the phenotype to acyl-donor availability, but abundance alone does not prove direct acyl transfer.
• Broad shifts across CL, PE, PC, and other mitochondrial lipids: support membrane-wide remodeling rather than a CL-specific event.

Parallel phospholipid profiling is most useful when the study asks whether CL changes are selective or part of a larger membrane response. The panel should remain hypothesis-led; adding many lipid classes without a predefined interpretation increases multiple testing without necessarily resolving the mechanism.

Fatty-acid supply must also be documented. Diet, serum, albumin-bound lipids, supplementation, and cell-density-dependent nutrient use can change acyl availability. Baseline and terminal fatty-acid context can prevent a substrate-driven change from being attributed solely to remodeling-enzyme regulation.

Oxidized Cardiolipin Analysis as a Separate Endpoint

Loss of a polyunsaturated CL species is not direct evidence of cardiolipin oxidation. The species may have been remodeled into another CL, hydrolyzed, depleted with mitochondria, or lost during extraction. Conversely, an unchanged parent pool does not exclude a small but biologically relevant oxidized fraction.

OxCL should be included when the hypothesis specifically concerns oxidative stress, apoptosis-related signaling, ischemia-reperfusion, ferroptosis-associated lipid peroxidation, or drug-induced mitochondrial injury. Define which hydroxy, hydroperoxy, or other oxidized products are targeted and whether they are reported quantitatively or semiquantitatively. A generic mass shift without retention and fragmentation support is not enough for a species-level OxCL claim.

Sample handling becomes part of the evidence. Polyunsaturated CL can oxidize after collection during warm delays, repeated freeze–thaw cycles, prolonged exposure to air or light, and poorly controlled extraction. Collection-to-freezing time, validated antioxidant use, extraction order, processed-sample stability, and blank or QC behavior should be documented.

OxCL results should be reported separately from remodeling metrics. An increased MLCL/CL ratio does not prove oxidation, and an OxCL increase does not by itself establish a remodeling defect. Connecting them requires measurement of parent CL, MLCL, selected oxidation products, mitochondrial context, and perturbation timing.

Experimental Controls for Cardiolipin Remodeling

A remodeling study should separate biological replication from analytical repetition. Independent animals, donors, cultures, or tissue preparations define biological sample size. Repeated extraction or injection of one pooled sample measures technical precision but does not increase biological inference.

Particularly informative controls include:

• a pooled study QC spanning the biological matrices and expected CL composition;
• extraction blanks and carryover blanks after high-abundance samples;
• internal standards added before extraction to monitor recovery;
• randomized or balanced extraction and injection order;
• a pilot dilution series to detect matrix-dependent nonlinearity;
• preparation replicates for isolated mitochondria when isolation variability is material;
• prespecified handling and freeze–thaw limits for oxidation-sensitive studies;
• time-course sampling when remodeling kinetics, rather than a terminal state, is the mechanism of interest.

Treatment effects on viability, cell number, tissue composition, and mitochondrial abundance should be measured in parallel. A late terminal time point can combine primary remodeling with secondary cell loss. Earlier time points may distinguish a molecular-species redistribution from subsequent depletion of the entire mitochondrial lipid pool.

The statistical model should reflect donor, animal, plate, isolation batch, extraction batch, and injection batch. Ratios and compositional summaries can be analyzed, but their component measurements should remain available for sensitivity analysis.

Reporting Cardiolipin Remodeling Results

The final report should preserve the evidence chain from sample to interpretation. At minimum, include:

• sample type, tissue region, culture conditions, and biological replicate definition;
• collection, storage, extraction, and mitochondrial-isolation metadata;
• the normalization basis and any mitochondrial-abundance marker;
• total CL and total MLCL values beside the MLCL/CL ratio;
• the exact species included in ratio calculations;
• CL and MLCL molecular-species tables with supported annotation levels;
• PG and other contextual phospholipids when used in the interpretation;
• internal-standard response, pooled-QC precision, blank review, carryover, missingness, and quantitative-range flags;
• separate reporting of OxCL targets and their oxidation-control evidence;
• statistical models, multiple-testing procedure, and component-level sensitivity analyses.

Interpretation should state whether the data support altered pool size, altered remodeling balance, molecular-species redistribution, broader mitochondrial depletion, or a combination. It should also identify unresolved alternatives. This is more informative than labeling every CL difference as “mitochondrial dysfunction” or every MLCL/CL increase as proof of one enzyme defect.

References:

1. Bird SS, Marur VR, Sniatynski MJ, Greenberg HK, Kristal BS. Lipidomics profiling by high-resolution LC-MS and high-energy collisional dissociation fragmentation: focus on characterization of mitochondrial cardiolipins and monolysocardiolipins. Analytical Chemistry. 2011;83(3):940–949. DOI: 10.1021/ac102598u.
2. Kappler L, et al. Purity matters: a workflow for the valid high-resolution lipid profiling of mitochondria from cell culture samples. Scientific Reports. 2016;6:21107. DOI: 10.1038/srep21107.
3. Oemer G, et al. Phospholipid acyl chain diversity controls the tissue-specific assembly of mitochondrial cardiolipins. Cell Reports. 2020;30(12):4281–4291.e4. DOI: 10.1016/j.celrep.2020.02.115.
4. Vaz FM, et al. An improved functional assay in blood spot to diagnose Barth syndrome using the monolysocardiolipin/cardiolipin ratio. Journal of Inherited Metabolic Disease. 2022;45(1):29–37. DOI: 10.1002/jimd.12425.
5. Xu Y, et al. Assembly of the complexes of oxidative phosphorylation triggers the remodeling of cardiolipin. Proceedings of the National Academy of Sciences. 2019;116(23):11235–11240. PubMed 31110016.
6. Wang S, et al. Cardiolipin remodeling defects impair mitochondrial architecture and function in a murine model of Barth syndrome cardiomyopathy. Circulation: Heart Failure. 2021;14(6):e008289. PubMed 34129362.
7. Kiebish MA, et al. Myocardial regulation of lipidomic flux by cardiolipin synthase: setting the beat for bioenergetic efficiency. Journal of Biological Chemistry. 2012;287(30):25086–25097. PubMed 22584571.
8. Moulin M, et al. Sex-specific cardiac cardiolipin remodelling after doxorubicin treatment. Biology of Sex Differences. 2015;6:20. DOI: 10.1186/s13293-015-0039-5.
9. Tyurina YY, et al. Mass-spectrometric analysis of hydroperoxy- and hydroxy-derivatives of cardiolipin and phosphatidylserine in cells and tissues induced by pro-apoptotic and pro-inflammatory stimuli. Journal of Chromatography B. 2009;877(26):2863–2872. DOI: 10.1016/j.jchromb.2009.03.007.
10. Liebisch G, et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. Journal of Lipid Research. 2020;61(12):1539–1555. DOI: 10.1194/jlr.S120001025.